Drug Modification Simulation Service
In the wave of drug development, optimizing the properties of existing drugs and exploring their broader potential for clinical application is of significant importance. Leveraging its leading computational biology technology, CD ComputaBio provides clients with professional drug modification simulation services, assisting you in efficiently and economically exploring the infinite possibilities of drug molecules.
Introduction to Drug Modification
Drug modification is the process of modifying drug molecules through chemical or physical methods, aiming to improve their pharmacokinetic, pharmacodynamic, stability, and bioavailability properties. Common modification methods include PEGylation, introducing hydrophilic groups, or altering the position of functional groups. Through these technologies, it is possible to prolong drug half-life, enhance solubility, reduce immunogenicity, and decrease adverse reactions, thereby increasing the clinical value of the drug.
Fig. 1 Structures of α-arbutin, β-arbutin, and molecular modification strategies of SPase in the synthesis of α-arbutin. (Zhang H, et al., 2024)
Computational Simulation of Drug Modification
Drug modification simulation utilizes computational methods to modify the structure of drug molecules in order to enhance their efficacy and safety. Through technologies such as molecular docking, molecular dynamics, and quantum mechanics, it analyzes drug-target binding modes and predicts the impact of key site modifications on affinity, selectivity, and metabolic stability. By employing AI algorithms, it designs highly active molecular variants, optimizes pharmacokinetic parameters, and reduces toxicity risks, thereby accelerating the rational design process of drugs for anti-cancer, anti-infection, and other therapeutic areas, and saving experimental costs.
Fig. 2 MD simulation analysis of compounds on the HpG6PD model. (Hernández-Ochoa B, et al., 2021)
Our Services
CD ComputaBio brings together a team of experienced computational biology experts and is equipped with advanced computing platforms and professional software tools. We are committed to providing you with high-quality, customized drug modification simulation services, including but not limited to:
- Nucleic Acid Drug Modification Simulation
- Antibody Drug Modification Simulation
- Protein Drug Modification Simulation
Methods for Drug Modification Simulation
Utilizing molecular docking to predict the binding mode of drug molecules to targets (such as proteins, nucleic acids, etc.), and evaluating binding affinity and selectivity. Analyzing the binding site provides a theoretical basis for drug modification.
Employing molecular dynamics simulation to study the dynamic behavior of drug molecules in a biological environment, and assessing their stability and conformational changes. Helping to optimize the structure of drugs, MD simulation improves their in vivo stability and bioavailability.
- Quantum Mechanics Calculation
Applying quantum mechanics calculations to analyze the electronic structure and reactivity of drug molecules, and predicting the chemical properties of key sites. Providing theoretical support for drug modification, QM calculations are valuable.
Leveraging artificial intelligence (AI) algorithms to design highly active drug molecule variants, optimizing pharmacokinetic parameters, and predicting potential toxicity risks.
Combining multi-scale simulation methods to comprehensively evaluate the performance of drug molecules from the atomic to the macroscopic level. Ensuring the stability and efficacy of drugs in different environments through multi-level optimization.
CD ComputaBio looks forward to collaborating with you to accelerate your drug development process. If you are interested in our drug modification simulation service, please feel free to contact us at any time. Our team will provide you with detailed consultation and professional support.
References:
- Zhang, H.; et al. Advancements in the Heterologous Expression of Sucrose Phosphorylase and Its Molecular Modification for the Synthesis of Glycosylated Products[J]. Molecules. 2024, 29(17): 4086.
- Hernández-Ochoa, B.; et al. Identification and in silico characterization of novel Helicobacter pylori glucose-6-phosphate dehydrogenase inhibitors[J]. Molecules. 2021, 26(16): 4955.
* For Research Use Only.
Related Services
